Esperion Therapeutics Inc.

NASDAQ:ESPR   3:58:51 PM EDT
20.98
-1.90 (-8.30%)
Products, Other Pre-Announcement

Esperion Reports Q1 2021 Financial Results

Published: 05/04/2021 20:35 GMT
Esperion Therapeutics Inc. (ESPR) - Esperion Reports First Quarter 2021 Financial Results and Provides Company Update.
Q1 Loss per Share $3.50.
Q1 Revenue $8.0 Million.
Esperion Therapeutics - Research and Development Expenses for Full Year 2021 Are Expected to Be $120 Million to $130 Million.
Esperion Therapeutics - Continues to Expect Full-year 2021 Operating Expenses to Be About $320 Million to $340 Million.
Q1 Earnings per Share View $-2.52 -- Refinitiv Ibes Data (analyst estimates).